HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $250
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $455 to $250.

Last updated: 2026-11-19 10:11:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alnylam Pharmaceuticals, Inc. (ALNY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $149.82, with a market capitalization of $20.96B and a P/E ratio of 7.69. Over the past 52 weeks, its price has ranged from $147.58 to $479.79. This page covers its latest market performance, valuation, price trends and company information.
$20.96B | |
$149.47 | |
$149.82 | |
$149.47 | |
$149.40 | |
357.00 | |
2.08M | |
7.69 | |
$479.79 | |
$147.58 | |
-- | |
2026-09-30 |
Alnylam Pharmaceuticals, Inc. (ALNY) is trading at $149.82 in pre-market trading as of 2026-11-19 09:59:00, up 0.28% ($0.42) from the previous close of $149.40
Pre-market trading shows how investors are pricing ALNY before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Alnylam Pharmaceuticals, Inc. (ALNY) moved from $151.64 to $149.82, representing a decline of 1.20% ($1.82).
The stock traded between $147.58 and $168.35 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2.81 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.7%
ALNY is currently trading at $149.82, placing it 0.7% of the way from its 52-week low of $147.58 to its 52-week high of $479.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2,500 |
| CEO | Yvonne L. Greenstreet |
| Founded | 2002 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Alnylam Pharmaceuticals, Inc. and ALNY stock.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $455 to $250.
Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.
Eligible investors can buy real shares of Alnylam Pharmaceuticals, Inc. (ALNY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ALNY, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ALNY shares and USD.
ALNY Shares to USD
1.00 ALNY shares = 149.82 USD
Calculations are estimates based on the latest available price and are for reference only.